Comera Life Sciences Holdings, Inc.

Symbol: CMRA

NASDAQ

0.041

USD

Market price today

  • -0.0112

    P/E Ratio

  • 0.0001

    PEG Ratio

  • 1.26M

    MRK Cap

  • 0.00%

    DIV Yield

Comera Life Sciences Holdings, Inc. (CMRA) Stock Price & Analysis

Shares Outstanding

30.74M

Gross Profit Margin

0.74%

Operating Profit Margin

-9.14%

Net Profit Margin

-84.22%

Return on Assets

-27.43%

Return on Equity

15.26%

Return on Capital Employed

-65.55%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Michael G. Campbell CPA
Full-time employees:12
City:Woburn
Address:12 Gill Street
IPO:2020-12-21
CIK:0001907685

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

General Outlook

In simple terms, Comera Life Sciences Holdings, Inc. has 30.738 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.735% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -9.143%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -84.219%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -27.426% return, is a testament to Comera Life Sciences Holdings, Inc.'s adeptness in optimizing resource deployment. Comera Life Sciences Holdings, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 15.261%. Furthermore, the proficiency of Comera Life Sciences Holdings, Inc. in capital utilization is underscored by a remarkable -65.555% return on capital employed.

Stock Prices

Comera Life Sciences Holdings, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.0361, while its low point bottomed out at $0.034. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Comera Life Sciences Holdings, Inc.'s stock market.

Liquidity Ratios

Analyzing CMRA liquidity ratios reveals its financial health of the firm. The current ratio of 89.70% gauges short-term asset coverage for liabilities. The quick ratio (63.70%) assesses immediate liquidity, while the cash ratio (60.29%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio89.70%
Quick Ratio63.70%
Cash Ratio60.29%

Profitability Ratios

CMRA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -900.56% underscores its earnings before tax deductions. The effective tax rate stands at -835.04%, revealing its tax efficiency. The net income per EBT, 935.18%, and the EBT per EBIT, 98.50%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -914.32%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-900.56%
Effective Tax Rate-835.04%
Net Income per EBT935.18%
EBT per EBIT98.50%
EBIT per Revenue-914.32%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.90, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 1000.40% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding64
Days of Inventory Outstanding-138
Operating Cycle-101.31
Days of Payables Outstanding1578
Cash Conversion Cycle-1679
Receivables Turnover10.00
Payables Turnover0.23
Inventory Turnover-2.65
Fixed Asset Turnover2.87
Asset Turnover0.33

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.29, and free cash flow per share, -1.53, depict cash generation on a per-share basis. The cash per share value, 0.08, showcases liquidity position. Lastly, the operating cash flow sales ratio, -6.66, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.29
Free Cash Flow per Share-1.53
Cash per Share0.08
Operating Cash Flow Sales Ratio-6.66
Free Cash Flow to Operating Cash Flow Ratio5.30
Cash Flow Coverage Ratio-38.82
Short Term Coverage Ratio-38.82
Capital Expenditure Coverage Ratio-0.23
Dividend Paid and Capex Coverage Ratio-0.23

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 5.59%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.04, we discern the balance between debt and equity financing. An interest coverage of -363.29 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio5.59%
Debt Equity Ratio-0.04
Total Debt to Capitalization-4.24%
Interest Coverage-363.29
Cash Flow to Debt Ratio-38.82
Company Equity Multiplier-0.73

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.06, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.30, reflects the portion of profit attributed to each share. The book value per share, -0.60, represents the net asset value distributed per share, while the tangible book value per share, -0.60, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.06
Net Income Per Share-2.30
Book Value Per Share-0.60
Tangible Book Value Per Share-0.60
Shareholders Equity Per Share-0.60
Interest Debt Per Share0.08

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 97.95%, indicates top-line expansion, while the gross profit growth, 166.15%, reveals profitability trends. EBIT growth, -116.24%, and operating income growth, -116.24%, offer insights into operational profitability progression. The net income growth, -354.31%, showcases bottom-line expansion, and the EPS growth, -721.43%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth97.95%
Gross Profit Growth166.15%
EBIT Growth-116.24%
Operating Income Growth-116.24%
Net Income Growth-354.31%
EPS Growth-721.43%
EPS Diluted Growth-721.43%
Weighted Average Shares Growth-45.24%
Weighted Average Shares Diluted Growth-45.24%
Operating Cash Flow Growth-160.03%
Free Cash Flow Growth-151.29%
10-Year Revenue Growth per Share161.01%
5-Year Revenue Growth per Share161.01%
3-Year Revenue Growth per Share161.01%
10-Year Operating CF Growth per Share-889.07%
5-Year Operating CF Growth per Share-889.07%
3-Year Operating CF Growth per Share-889.07%
10-Year Net Income Growth per Share-1965.17%
5-Year Net Income Growth per Share-1965.17%
3-Year Net Income Growth per Share-1965.17%
10-Year Shareholders Equity Growth per Share-7609.14%
5-Year Shareholders Equity Growth per Share-7609.14%
3-Year Shareholders Equity Growth per Share-7609.14%
Receivables Growth-84.51%
Inventory Growth125364.15%
Asset Growth-49.75%
Book Value per Share Growth22.33%
Debt Growth139.91%
R&D Expense Growth-0.73%
SGA Expenses Growth170.26%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 13,185,258.31, captures the company's total value, considering both debt and equity. Income quality, 0.54, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 16.83, gauges operational efficiency, while the research and development to revenue, 274.81%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value13,185,258.31
Income Quality0.54
Sales General and Administrative to Revenue16.83
Research and Development to Revenue274.81%
Capex to Operating Cash Flow0.29%
Capex to Revenue-4.52%
Capex to Depreciation-30.45%
Stock-Based Compensation to Revenue59.36%
Graham Number5.56
Return on Tangible Assets-644.95%
Graham Net Net-0.79
Working Capital-1,995,584
Tangible Asset Value-6,247,088
Net Current Asset Value-6,911,103
Average Receivables127,937
Average Payables937,604
Average Inventory1,255,641.5
Days Sales Outstanding20
Days Payables Outstanding2530
Days of Inventory On Hand4353
ROIC292.06%
ROE3.85%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.22, and the price to book ratio, -0.22, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.26, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.04, and price to operating cash flows, -0.14, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-0.22
Price to Book Ratio-0.22
Price to Sales Ratio1.26
Price Cash Flow Ratio-0.14
Enterprise Value Multiple-0.31
Price Fair Value-0.22
Price to Operating Cash Flow Ratio-0.14
Price to Free Cash Flows Ratio-0.04
Price to Tangible Book Ratio-2.06
Enterprise Value to Sales20.83
Enterprise Value Over EBITDA-0.99
EV to Operating Cash Flow-1.35
Earnings Yield-186.97%
Free Cash Flow Yield-76.23%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Comera Life Sciences Holdings, Inc. (CMRA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.011 in 2024.

What is the ticker symbol of Comera Life Sciences Holdings, Inc. stock?

The ticker symbol of Comera Life Sciences Holdings, Inc. stock is CMRA.

What is company IPO date?

IPO date of Comera Life Sciences Holdings, Inc. is 2020-12-21.

What is company current share price?

Current share price is 0.041 USD.

What is stock market cap today?

The market cap of stock today is 1260250.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 12.